Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Friday . The company traded as high as C$12.15 and last traded at C$12.14, with a volume of 809 shares traded. The stock had previously closed at C$11.89.
Fennec Pharmaceuticals Stock Up 2.3%
The business has a 50 day moving average of C$10.37 and a 200-day moving average of C$9.34. The stock has a market cap of C$234.50 million, a PE ratio of -205.99 and a beta of 0.25. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83.
Insider Buying and Selling
In related news, Senior Officer Robert Christopher Andrade acquired 8,220 shares of the firm's stock in a transaction on Monday, June 2nd. The stock was bought at an average cost of C$6.99 per share, with a total value of C$57,433.14. Also, Director Jeffrey Hackman acquired 15,000 shares of the firm's stock in a transaction on Monday, May 19th. The shares were bought at an average cost of C$9.77 per share, with a total value of C$146,580.00. Insiders have sold 38,076 shares of company stock worth $391,650 in the last quarter. 16.20% of the stock is owned by insiders.
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.
Read More
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.